\
&
Contact us
\
&
Contact us
Published on | 1 month ago
ProgrammesAENAON, a Digital Europe-funded project, has opened the first of two cascade funding calls.
Open Call 1 focuses on the initial validation, integration, and testing of AENAON technologies and services in realistic offshore wind and related critical-infrastructure environments.
The objective of Open Call 1 is to strengthen the technical and operational foundations of the AENAON ecosystem by enabling external organisations to integrate with, test and validate AENAON technologies and services through targeted offshore-wind cybersecurity use cases.
The call is open to single applicants or small consortia combining complementary expertise, where this strengthens the proposed use case and contributes to the objectives of the AENAON project.
Detailed information on the call objectives and scope, the procedure and selection criteria can be found on the dedicated website of the AENAON project.
Deadline to submit proposals is 13 November 2026.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.
